Plant Form Header
PlantForm financing tops $1M

PlantForm Corporation made significant progress in 2010 as we work to bring our first anti-cancer drug, biosimilar trastuzumab, towards market. Here are some highlights of the past year:
  • To date, PlantForm has raised a total of $1.15 million in cash and kind from shareholders, including $250,000 over the last six months. This enables us to continue the critical development activities of the company.
  • The National Research Council recently awarded PlantForm a $50,000 Industrial Research Assistance Program grant for market evaluation and intellectual property development over the next six months. We continue to source additional investments to fund ongoing scientific activities.
  • Our first manufacturing run of biosimiar trastuzumab is now under way at Kentucky BioProcessing’s U.S. plant, in preparation for animal studies. KBP is optimizing and scaling up the production and purification processes in accordance with standard pharmaceutical practices.
  • Our product will be tested in animal models in early 2011.
  • A seminal research paper published in 2010 shows PlantForm’s biosimilar trastuzumab is as effective as the commercial antibody drug Herceptin at inhibiting the growth of HER2-positive breast cancer cells in laboratory tests.
  • PlantForm was also honoured to be named Guelph’s Innovator of the Year and, for the second time, one of Canada’s Top 10™ life science investment prospects.
On behalf of the PlantForm team, I thank our shareholders, partners and friends for your support and wish you a happy and prosperous 2011.

Mark Goldberg, PhD, DABT, C.Dir.
Chairman of the Board of Directors

Industry news

EMA issues draft biologics guideline
The European Medicines Agency has outlined draft requirements for similar biological medicinal products containing monoclonal antibodies. The deadline for comments is May 31, 2011.
Germany moves to control costs for new drugs
New law governs price of innovative drugs in Europe’s biggest market, Bloomberg reports.

China cuts selected drug prices
China aims to reel in health-care costs as the world's third-largest drug market is expected to grow at least 25 per cent next year due to a new national health insurance system.

Winter 2010

Upcoming Events

Canada’s Top 10™ tour
PlantForm plans to take part in Canada’s Top 10™ investment forums in California’s Silicon Valley (Jan. 11), Boston and New York (Jan. 18-21) and Washington D.C. (date TBD).

The forums are an exclusive opportunity to present to top-tier U.S. and Canadian venture capitalists, licensing executives and potential strategic partners. 

BioPartnering North America
PlantForm will also present its investment case at the 9th annual BioPartnering North America conference in Vancouver Feb. 27-March 1.

Advancing protein science
Dr. Chris Hall, PlantForm’s Chief Scientific Officer, will give a talk on Purification of Plant-Derived Antibodies through Direct Immobilization of Affinity Ligands on Cellulose, at Cambridge Healthtech Institute’s PEP TALK: The Protein Science Week, Jan. 10-14 2011 in San Diego, Calif.

Management Team

Don Stewart, PhD
President & CEO

Ron Hosking, CA
Chief Financial Officer

Chris Hall, PhD
Chief Scientific Officer

PlantForm is a Canadian company focused on providing
low-cost therapeutic antibody drugs that fight cancer and other critical illnesses.

Our mailing address is:
1920 Yonge St, Suite 200
Toronto, Ontario
For more information, contact:
Don Stewart
President & CEO